Lykos Therapeutics is laying off about 100 employees, roughly 75% of its workforce, following the FDA's rejection of its approval request. The restructuring aims to support the company's efforts to refile an approval application.
The remaining skeleton team will focus on ongoing clinical development, medical affairs, and FDA engagement. The company also appointed David Hough, a former Johnson & Johnson executive, to oversee the clinical development program and FDA engagement for the planned resubmission.
Furthermore, Founder Rick Doblin has resigned from Lykos' board to focus on advocacy work. A newly formed independent advisory board will support management during the resubmission process and maintain contact with behavioral health facilities and key patient stakeholder groups.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.